Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.

Sara Blanco DoradoOlalla MaroñasAna Latorre-PellicerMaría Teresa Rodríguez JatoAna López-VizcaínoAurea Gómez MárquezBelén Bardán GarcíaDolores Belles MedallGema Barbeito CastiñeirasMaría Luisa Pérez Del Molino BernalManuel Campos-ToimilFrancisco Otero EspinarAndrés Blanco HortasGoretti Durán PiñeiroIrene Zarra FerroÁngel CarracedoMaría Jesús LamasAnxo Fernández-Ferreiro

Published in: Pharmacotherapy (2020)

These results suggest the potential clinical utility of using CYP2C19 genotype-guided voriconazole dosing to achieve concentrations in the therapeutic range in the early course of therapy. Larger studies are needed to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics.

Keyphrases

case control
mesenchymal stem cells
risk assessment
human health
bone marrow